SOPHiA GENETICS (NASDAQ:SOPH) CTO Sells $38,261.44 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) CTO Abhimanyu Verma sold 6,944 shares of the stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $5.51, for a total value of $38,261.44. Following the sale, the chief technology officer directly owned 197,456 shares of the company’s stock, valued at $1,087,982.56. The trade was a 3.40% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Abhimanyu Verma also recently made the following trade(s):

• On Tuesday, April 7th, Abhimanyu Verma sold 1,030 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.87, for a total transaction of $5,016.10.
• On Monday, April 6th, Abhimanyu Verma sold 2,519 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.86, for a total transaction of $12,242.34.

SOPHiA GENETICS Stock Performance

NASDAQ:SOPH opened at $5.75 on Monday. The company has a debt-to-equity ratio of 1.05, a current ratio of 2.06 and a quick ratio of 1.90. The business has a fifty day simple moving average of $5.07 and a two-hundred day simple moving average of $4.92. SOPHiA GENETICS SA has a 1 year low of $2.81 and a 1 year high of $5.94. The company has a market capitalization of $482.37 million, a P/E ratio of -11.06 and a beta of 0.98.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.27) EPS for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The firm had revenue of $21.69 million for the quarter, compared to analysts’ expectations of $20.40 million. SOPHiA GENETICS had a negative net margin of 44.48% and a negative return on equity of 62.74%.

Analysts Set New Price Targets

Several research firms recently commented on SOPH. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Tuesday, April 21st. BTIG Research reiterated a “buy” rating and issued a $8.00 price target on shares of SOPHiA GENETICS in a research report on Monday, June 15th. Two research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $7.50.

Institutional Trading of SOPHiA GENETICS

Hedge funds and other institutional investors have recently bought and sold shares of the company. First Dallas Securities Inc. purchased a new position in shares of SOPHiA GENETICS in the first quarter worth about $50,000. Squarepoint Ops LLC bought a new position in SOPHiA GENETICS during the 3rd quarter worth approximately $49,000. Perkins Capital Management Inc. purchased a new position in SOPHiA GENETICS in the 4th quarter worth approximately $49,000. Quadrature Capital Ltd purchased a new position in SOPHiA GENETICS in the 4th quarter worth approximately $54,000. Finally, XTX Topco Ltd bought a new stake in SOPHiA GENETICS in the fourth quarter valued at approximately $55,000. Hedge funds and other institutional investors own 31.59% of the company’s stock.

About SOPHiA GENETICS

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.